Exelixis $EXEL Cabometyx bettered Pfizer’s Sutent in mid-stage kidney cancer study. The Phase 2 clinical trial, CABOSUN, evaluating CABOMETYX (cabozantinib) demonstrated better response in treatment-naive patients with advanced renal cell carcinoma (RCC). The data were presented at the European Society for Medical Oncology 2016 Annual Meeting in Copenhagen.